Search results for "CAP"

showing 10 items of 8832 documents

Effects of combined endurance and strength training on muscle strength, power and hypertrophy in 40-67-year-old men

2009

Both strength and endurance training have several positive effects on aging muscle and physical performance of middle-aged and older adults, but their combination may compromise optimal adaptation. This study examined the possible interference of combined strength and endurance training on neuromuscular performance and skeletal muscle hypertrophy in previously untrained 40-67-year-old men. Maximal strength and muscle activation in the upper and lower extremities, maximal concentric power, aerobic capacity and muscle fiber size and distribution in the vastus lateralis muscle were measured before and after a 21-week training period. Ninety-six men [mean age 56 (SD 7) years] completed high-int…

medicine.medical_specialtyStrength trainingbusiness.industryVastus lateralis musclePhysical Therapy Sports Therapy and RehabilitationMuscle hypertrophyEndurance trainingInternal medicineOne-repetition maximumMuscle strengthmedicinePhysical therapyCardiologyOrthopedics and Sports MedicineMuscle fibrebusinessAerobic capacityScandinavian Journal of Medicine & Science in Sports
researchProduct

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

2020

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune thrombotic microangiopathy. Caplacizumab, an anti-von Willebrand Factor Nanobody® , is effective for treating aTTP episodes and is well tolerated. OBJECTIVES AND METHODS In the phase 3 HERCULES trial (NCT02553317), patients with aTTP received double-blind caplacizumab or placebo during daily therapeutic plasma exchange (TPE) and for ≥30 days thereafter. Patients who experienced an exacerbation while on blinded study drug treatment switched to receive open-label caplacizumab plus re-initiation of daily TPE. Exacerbations were defined as recurrence of disease occurring within 30 days after ce…

medicine.medical_specialtyThrombotic microangiopathyExacerbation610 Medicine & health030204 cardiovascular system & hematologyvon Willebrand factorPlacebocaplacizumabthrombotic thrombocytopenic03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicineMedicineHumansPlatelet610 Medicine & healthAdverse effectADAMTS13 proteinAcquired Thrombotic Thrombocytopenic PurpurabiologyPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryBrief ReportHematologySingle-Domain Antibodiesmedicine.diseaseTHROMBOSISpurpurabiology.proteinCaplacizumabbusinessJournal of thrombosis and haemostasis : JTH
researchProduct

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

2021

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi. TTP results from a severe deficiency of the specific von Willebrand factor (VWF)-cleaving protease, ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13). ADAMTS13 deficiency is most commonly acquired due to anti-ADAMTS13 autoantibodies. It can also be inherited in the congenital form as a result of biallelic mutations in the ADAMTS13 gene. In adults, the condition is most often immune-mediated (iTTP) whereas congenital TTP (cTT…

medicine.medical_specialtyThrombotic microangiopathyTTPdiagnosisThrombotic thrombocytopenic purpuralcsh:MedicineReview030204 cardiovascular system & hematologycaplacizumabGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorhemic and lymphatic diseasesInternal medicinefollow-upmedicinethrombotic thrombocytopenic purpuratreatmentbiologybusiness.industrylcsh:RGeneral MedicineMicroangiopathic hemolytic anemiamedicine.diseaseADAMTS13ADAMTS13biology.proteinRituximabFresh frozen plasmaCaplacizumabbusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

Effect of Atrial Capture Beats on the Subsequent Cycle During Slow Common Atrioventricular Nodal Reentry Tachycardia

2013

medicine.medical_specialtyTime Factorsmedicine.diagnostic_testbusiness.industryCardiac anatomyAtrial arrhythmiasMiddle AgedNodal diseasePredictive Value of TestsPhysiology (medical)Predictive value of testsInternal medicineAtrial captureElectrocardiography AmbulatoryTachycardia SupraventricularmedicineCardiologyHumansTachycardia Atrioventricular Nodal ReentryTachycardia ParoxysmalCardiology and Cardiovascular MedicinebusinessElectrocardiographyJournal of Cardiovascular Electrophysiology
researchProduct

Differentialdiagnose Berylliose/Sarkoidose bei einem Zahntechniker

2008

History and clinical findings Sarcoidosis was diagnosed in a dental technician when he was aged 21 years. Two years later prednisolone treatment was started and continued for 14 years because of nonproductive cough with progressive reduction in vital capacity and CO transfer capacity. Subsequently the risk of exposure to beryllium-containing dust in dental laboratories became known. In his case exposure had started before sarcoidosis had been diagnosed and had continued for 16 years. Changes typical of sarcoidosis (unproductive cough and dyspnoea; bihilar lymphadenopathy and reticulonodular marking in the chest radiogram) were now present, at the age of 40 years. Investigations Vital and di…

medicine.medical_specialtyTransfer capacityBerylliosisbusiness.industryNeopterinpeople.professionGeneral MedicineDental technicianmedicine.diseaseDermatologyrespiratory tract diseaseschemistry.chemical_compoundchemistrymedicinePrednisoloneSarcoidosisDifferential diagnosisUnproductive coughpeoplebusinessmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

Alveolar echinococcosis: characteristics of a possible emergence and new perspectives in epidemiosurveillance

2001

International audience; The aim of this review is to discuss the situation of alveolar echinococcosis in France, in the light of the current knowledge on its transmission patterns in the world, especially Europe. An important risk of higher contamination of the rural environment may be suspected from newly reported cases of infected foxes or voles in several countries where the disease was not found before. Furthermore, the increase of prevalence rate in foxes in Bade-Würtemberg (Germany) and Franche-Comté (France), traditionally endemic, is also in support of this new trend. Urban foxes and the spreading of infected foxes to cities may also be the cause of the extension to urban and suburb…

medicine.medical_specialtyVeterinary medicinefoxLandscape epidemiologyepidemiosurveillance030231 tropical medicinePrevalencecoprotestEchinococcus multilocularis030308 mycology & parasitologylaw.invention[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciences0302 clinical medicinelandscape epidemiologylawEnvironmental healthEpidemiologymedicine[SDV.EE]Life Sciences [q-bio]/Ecology environment0303 health sciencesbiologyPublic healthZoonosismedicine.diseasebiology.organism_classification3. Good health[SDV.EE] Life Sciences [q-bio]/Ecology environmentInfectious DiseasesTransmission (mechanics)GeographyEchinococcus multilocularisRural area
researchProduct

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.

2011

Purpose: This study evaluated the safety and effectiveness of long-term enzyme replacement therapy with idursulfase (recombinant human iduronate-2-sulfatase) in patients with Hunter syndrome. Methods: All 94 patients who completed a 53-week double-blinded study of idursulfase enrolled in this open-labeled extension study and received intravenous idursulfase at a dose of 0.5 mg/kg weekly for 2 years, and clinical outcomes and safety were assessed. Results: No change in percent predicted forced vital capacity was seen, but absolute forced vital capacity demonstrated sustained improvement and was increased 25.1% at the end of the study. Statistically significant increases in 6-minute walking t…

medicine.medical_specialtyVital capacityAdolescentIdursulfaseIduronate SulfatasePulmonary function testingInternal medicineMedicineHumansEnzyme Replacement TherapyMucopolysaccharidosis type IIAdverse effectChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IIbusiness.industryPercent Predicted Forced Vital CapacityHunter syndromeEnzyme replacement therapyOrgan Sizemedicine.diseaseSurgeryTreatment OutcomeLiverChild PreschoolbusinessSpleenmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Objectifying acupuncture effects by lung function and numeric rating scale in patients undergoing heart surgery.

2012

Rationale. Poststernotomy pain and impaired breathing are common clinical problems in early postoperative care following heart surgery. Insufficiently treated pain increases the risk of pulmonary complications. High-dose opioids are used for pain management, but they may cause side effects such as respiratory depression.Study Design. We performed a prospective, randomized, controlled, observer-blinded, three-armed clinical trial with 100 patients. Group 1 (n=33) and Group 2 (n=34) received one 20 min session of standardized acupuncture treatment with two different sets of acupoints. Group 3 (n=33) served as standard analgesia control without additional intervention. Results. Primary endpoin…

medicine.medical_specialtyVital capacityArticle Subjectbusiness.industryAnalgesiclcsh:Other systems of medicinelcsh:RZ201-999Pulmonary function testingSurgeryClinical trialFEV1/FVC ratioComplementary and alternative medicineStatistical significanceAcupuncturemedicineClinical endpointbusinessResearch ArticleEvidence-based complementary and alternative medicine : eCAM
researchProduct

Abdominal wall incisional hernia repair improves respiratory function: results after 3 years of follow-up

2020

Abstract Purpose Hernias severely impact patient quality of life (QoL), and 80% of patients require a surgical operation. Moreover, hernias are responsible for respiratory function alterations. This study aims to investigate the postoperative alterations in respiratory function after open ventral hernia repair in patients with incisional hernia. Methods Patients operated on at the Policlinico “Paolo Giaccone” at Palermo University Hospital between January 2015 and December 2016 were identified in a prospective database. Fifty-one patients were enrolled in the study. The respiratory outcome measures used were forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC ratio…

medicine.medical_specialtyVital capacityIncisional herniaVentral hernia repairAbdominal wallFEV1/FVC ratioQuality of lifemedicineHumansRespiratory functionRespiratory systemRespiratory outcomeIncisional herniaHerniorrhaphybusiness.industryAbdominal Wallrespiratory systemmedicine.diseaseHernia Ventralrespiratory tract diseasesSurgerymedicine.anatomical_structureQuality of LifeOriginal ArticleSurgerybusinesscirculatory and respiratory physiologyFollow-Up StudiesAbdominal surgery
researchProduct

Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

2020

Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds…

medicine.medical_specialtyVital capacityIndolesPyridones03 medical and health scienceschemistry.chemical_compoundFEV1/FVC ratioIdiopathic pulmonary fibrosis0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)In patient030212 general & internal medicinebusiness.industryPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisTreatment Outcome030228 respiratory systemchemistryMeta-analysisNintedanibbusinessAll cause mortalitymedicine.drugThe Annals of pharmacotherapy
researchProduct